Feedback
Settings

Settings

Goto Application

545 results
Offices wo Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
PCT
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

FP:(drug design)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 55
1.WO/2024/082909DETECTION METHOD FOR MONITORING SYNTHESIS OF RNA BY IN VITRO TRANSCRIPTION IN REAL TIME
WO - 25.04.2024
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/CN2023/120252 Applicant SHANGHAI SHENDAO BIOTECHNOLOGY CO., LTD. Inventor YANG, Guangyu
A detection method for monitoring synthesis of RNA by in vitro transcription in real time, relating to the technical field of molecular biology and transcription. A DNA template suitable for in vitro transcription and a real-time fluorescent transcription system are developed, and a high-throughput, simple and sensitive RNA synthesis monitoring and quantification system is established. The DNA template/real-time fluorescent transcription system/monitoring system can be applied to synthesizing mRNA vaccines, screening RNA polymerases, analyzing promoter strength, screening drugs for inhibiting transcription, optimizing mRNA drug production process, training mRNA drug sequence AI design software and the like, and can further be applied to optimizing an in vitro transcription system, quantifying RNA polymerase activity, and optimizing sequences.
2.WO/2024/052340PREDICTION OF PHARMACOKINETIC PROPERTIES OF CHEMICAL COMPOUNDS
WO - 14.03.2024
Int.Class G16C 20/30
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
30Prediction of properties of chemical compounds, compositions or mixtures
 Appl.No PCT/EP2023/074320 Applicant F. HOFFMANN-LA ROCHE AG Inventor GROEBKE ZBINDEN, Katrin
Prediction of pharmacokinetic properties of chemical compounds A computer-implemented method of generating a machine-learning model configured to predict the value of one or more pharmacokinetic parameters of a pharmaceutical compound having a chemical structure comprises: receiving training data comprising a plurality of records, each record comprising: data encoding the chemical structure of a pharmaceutical compound; and the values of one or more pharmacokinetic parameters obtained from measurements taken from a human or animal subject after administration of the compound to the human or animal subject; and training the machine-learning model using the training data. Computer-implemented methods of utilizing the generated machine-learning model, particularly in a drug design context, are also provided.
3.WO/2024/051308PEMETREXED NEAR-INFRARED FLUORESCENT MOLECULE TARGETING α-TYPE FOLATE RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 14.03.2024
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/CN2023/103821 Applicant NANJING NUOYUAN MEDICAL DEVICES CO., LTD Inventor CAI, Huiming
Disclosed are a pemetrexed near-infrared fluorescent molecule targeting an α-type folate receptor, a preparation method therefor, and use thereof. The structural formula of the pemetrexed near-infrared fluorescent molecule is: . The pemetrexed near-infrared fluorescent molecule targeting the α-type folate receptor can be applied to the preparation of a drug for treating non-small cell lung cancer. By means of the comparison of the efficacy on non-small cell lung cancer between the clinically approved non-small cell lung cancer chemotherapeutic drug pemetrexed and the novel pemetrexed near-infrared fluorescent molecule, it is found that compared with pemetrexed, the novel pemetrexed near-infrared fluorescent molecule has a three-fold increase in the growth inhibition effect on non-small cell lung cancer, and shows a significant difference in inhibiting tumor tissue growth. Meanwhile, the design strategy of the molecule is to combine the obtained clinically approved therapeutic agents, so that the molecule has good druggability and biological safety.
4.WO/2024/042504MULTI-FUNCTIONAL CONTRACEPTIVE AND SEXUALLY TRANSMITTED DISEASE (STD) PREVENTIVE UNDERWEAR/SHORT WITH MULTIPLE INTELLIGENT CAPABILITIES IN SITU LOCAL DRUG DELIVERY AND TARGETED DRUG DELIVERY
WO - 29.02.2024
Int.Class A61F 6/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
6Contraceptive devices; Pessaries; Applicators therefor
06for use by females
08Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
 Appl.No PCT/IB2023/060472 Applicant MOGHARABIAN, Nasser Inventor MOGHARABIAN, Nasser
The design of a preventive health device for sexually transmitted diseases (STD) has been improved and consists of several different parts and contains different drug delivery platforms with various drug delivery mechanisms, in order to create a protective barrier in preventing pregnancy and increasing the quality of intercourse and increasing the speed and probability of reaching orgasm, especially in the female sex, which more effectively minimizes the possibility of contracting various sexually transmitted diseases And also, in addition to creating a healthier, more carefree and enjoyable experience of sexual intercourse, it is possible to transfer drugs with the desired therapeutic indication through the claimed platforms based on different drug delivery mechanisms, such as the bio-adhesive system in intravaginal drug delivery, the transdermal skin drug delivery system and the specific type of targeted drug delivery based on the production of bio-motors based on sperm, suitable for the type of disease.
5.WO/2024/022532COATING FOR MEDICAL DEVICE
WO - 01.02.2024
Int.Class A61L 31/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
31Materials for other surgical articles
08Materials for coatings
10Macromolecular materials
 Appl.No PCT/CN2023/110241 Applicant BIOTYX MEDICAL (SHENZHEN) CO., LTD. Inventor LI, Yunfei
A coating for a medical device. The coating comprises a drug-loaded layer and a drug controlled-release layer covering the drug-loaded layer. The molecular weight retention rate m of a polymer in the drug controlled-release layer, the weight-average molecular weight Mw controlled release of the polymer, and the thickness Xcontrolled release of the polymer meet the following relational expression; wherein A1, A2, k, and b are all fitting constants. The design of the coating not only can improve the release performance of a drug, but also can effectively control the corrosion of a matrix, so that the matrix of a degradable medical device cannot be degraded or can be slowly degraded within 1-6 months, and can be quickly degraded after 6 months.
6.WO/2023/244561MEDICAL DELIVERY ASSEMBLY
WO - 21.12.2023
Int.Class A61J 1/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
1Containers specially adapted for medical or pharmaceutical purposes
05for collecting, storing or administering blood, plasma or medical fluids
14Details; Accessories therefor
20Arrangements for transferring fluids, e.g. from vial to syringe
 Appl.No PCT/US2023/025123 Applicant KOSKA FAMILY LIMITED Inventor GIBNEY, Eric Dwyer
A pre-filled medical delivery assembly assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery assembly generally includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another. In accordance with some embodiments, the medical delivery assembly comprises a hub connector that includes at least one alignment track on an interior portion thereof, configured to receive a corresponding wing of a BFS vial which it is designed to couple with.
7.WO/2023/241675POLYPEPTIDE AND DESIGN METHOD THEREFOR, AND APPLICATION THEREOF IN PREPARING DRUG FOR INHIBITING FUSOBACTERIUM NUCLEATUM PRODUCT OR PREVENTING COLORECTAL CANCER
WO - 21.12.2023
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/CN2023/100589 Applicant SUN YAT-SEN UNIVERSITY Inventor ZHAO, Wenjing
Disclosed are a polypeptide and a design method therefor, and an application thereof in preparing a drug for inhibiting a Fusobacterium nucleatum (F. Nucleatum) product or preventing colorectal cancer, relating to the field of polypeptides. The polypeptide comprises hydrophobic amino acids and charged amino acids, and the amino acid sequence of the polypeptide is distributed as a symmetrical structure. The polypeptide of the present application takes natural amino acid residues as basic components, has inherent biocompatibility and biodegradability, can specifically kill F. nucleatum, has relatively low antibacterial activity on other bacteria, and does not have the side effect of antibiotics killing normal flora. Therefore, the polypeptide can be used for long-term limiting of in vivo F. nucleatum loading, and thus implements treatment and prevention of various F. nucleatum-related diseases. In addition, the polypeptide has advantages such as having a rapid sterilization rate, being residue-free and pollution-free, and having a highly flexible molecular composition and low immunogenicity.
8.WO/2023/235753ALDH2 INHIBITORS AND METHODS OF USE THEREOF
WO - 07.12.2023
Int.Class A61P 25/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
30for treating abuse or dependence
32Alcohol-abuse
 Appl.No PCT/US2023/067695 Applicant UNIVERSITY OF MARYLAND, BALTIMORE Inventor XUE, Fengtian
Substituted chromen-2-one compounds, synthesized using computer-aided virtual screening in combination with structure-based drug design (SBDD), for inhibiting the enzymatic activity of alcohol dehydrogenase-2 (ALDH2) and liver-specific OATP1-dependent uptake, pharmaceutical compositions thereof, and methods of using the same for the treatment of alcohol use disorders (AUDs) are disclosed. In some embodiments, the inventive compounds inhibit liver-specific ALDH2 protein.
9.WO/2023/226351SMALL-MOLECULE GENERATION METHOD BASED ON PHARMACOPHORE MODEL, AND DEVICE AND MEDIUM
WO - 30.11.2023
Int.Class G16C 20/50
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
50Molecular design, e.g. of drugs
 Appl.No PCT/CN2022/136051 Applicant CENTRAL SOUTH UNIVERSITY Inventor LI, Min
A small-molecule generation method based on a pharmacophore model, and a device and a medium. The method comprises: representing a pharmacophore model by a fully connected graph; extracting a feature vector of the pharmacophore model from the fully connected graph of the pharmacophore model by using a feature extraction model based on a graph neural network; performing random sampling on a specified latent variable distribution, so as to obtain a latent variable; and inputting the latent variable and the feature vector of the pharmacophore model into a pre-trained decoder, so as to generate molecules matching the pharmacophore model, wherein the trained decoder is a decoder obtained by training a variational autoencoder by using a training sample. The method can be applied to ligand-based drug design, receptor-based drug design, optimization of lead compounds and the finding of substitutes addressing drug resistance, and is used for constructing molecular databases for virtual screening, such that molecular screening based on large-scale federated databases is replaced. Therefore, blind experimental works are reduced, the time and cost for researching and developing drugs are saved on, and the pressure on researching and developing drugs is relieved.
10.WO/2023/221184PROTAC TARGET MOLECULE GENERATION METHOD, COMPUTER SYSTEM AND STORAGE MEDIUM
WO - 23.11.2023
Int.Class G16C 20/50
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
50Molecular design, e.g. of drugs
 Appl.No PCT/CN2022/096712 Applicant HUIYI KEJI ( SHANGHAI ) LTD. Inventor JIN, Yutong
Provided in the embodiments of the present description are a PROTAC target molecule generation method, a computer system and a storage medium. The molecule generation method comprises the steps: acquiring three parameters; extracting target protein ligand structures corresponding to a first parameter from a target protein ligand database so as to form a first subset, extracting degradation agent fragment structures corresponding to a second parameter from a degradation agent fragment database so as to form a second subset, and extracting linker fragment structures corresponding to a third parameter from a linker fragment database so as to form a third subset; and arranging and combining the fragment structures in the first subset, the second subset and the third subset to generate PROTAC target molecules. In the method, the fragment structures meeting requirements are extracted from each database, and then the three groups of fragment structures are arranged and combined to efficiently generate, by means of big data and computational processing, the PROTAC target molecules for use in follow-up experiments, thereby avoiding omissions in combinations of structural fragments, improving the precision of molecular design, and accelerating the whole drug research and development process.
# -